Tech Company Financing Transactions
Synta Pharmaceuticals Funding Round
On 7/11/2006, Synta Pharmaceuticals landed $40 million in Series E financing from Aperture Venture Partners.
Transaction Overview
Company Name
Announced On
7/11/2006
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series E
Investors
Proceeds Purpose
The company plans to use the funds to advance multiple clinical and pre-clinical programs. A combination of existing and undisclosed new institutional investors participated in the financing round.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
200 Barr Harbor Dr. 400
West Conshohocken, PA 19428
USA
West Conshohocken, PA 19428
USA
Phone
Undisclosed
Website
Email Address
Overview
Synta Pharmaceuticals (Nasdaq: SNTA) is a pharmaceutical company focused on discovering, developing, and commercializing breakthrough products for severe medical conditions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Paul Friedman
Chief Financial Officer
Marc Schneebaum
Chief Medical Officer
Rebecca Taub
Browse more venture capital transactions:
Prev: 7/11/2006: SkyPilot Networks venture capital transaction
Next: 7/11/2006: Ocera Therapeutics venture capital transaction
Share this article
Where The Data Comes From
We do our best to document funding rounds that are announced publicly. VC transactions reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs